⭐

Stryker Corporation

SYKDividend Aristocrat • 31yrs
Healthcare · Medical Devices🇺🇸 United States
$313.08
Dividend Yield1.11%
Annual Dividend$3.52
Ex-Dividend DateSep 30, 2026
Market Cap$119.19B
100/ 100
Financial Health
Healthy
Well-covered payout (37%)Conservative leverage (D/E 0.7x)Strong ROE (16%)Revenue growing (8%)

Automated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.

At a glance

Stryker Corporation (SYK) operates in the Medical Devices industry and is based in the United States. It pays a quarterly dividend of $3.52 a year, a yield of 1.11% at the current price of $313.08. Stryker has raised its dividend for 31 consecutive years, which makes it a Dividend Aristocrat. Over the last five years the dividend has grown by an average of 7.6% a year. It paid out 37% of its earnings as dividends, leaving most of its profit in the business. 28 analysts cover it; their average 12-month price target of $341.48 is 9.1% above the current price.

Written automatically from the figures on this page, as of Nov 20, 2026. Facts only, not a recommendation.

Price History
Dividend payment dates
Analyst Consensus
Buy
Bullish sentiment
79% of 28 analysts bullish
12-Month Price Target
$341.48
+9.1% vs current price

About Stryker Corporation

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products.

Business description from Yahoo Finance. Verify details in the company's own annual report.

Key Metrics

Valuation

P/E Ratio
33.3
P/B Ratio
5.08
EV/EBITDA
17.5
Beta
0.77
vs S&P 500
52W High
$389.33
52W Low
$267.00

Profitability

Gross Margin
65.70%
Operating Margin
23.97%
Net Margin
13.78%
ROE
16.02%
Free Cash Flow
$3.70B

Financial Health

Debt / Equity
0.66x
total debt ÷ equity; lower is safer
Current Ratio
2.18
>1 healthy
Quick Ratio
1.07
>1 healthy
Employees
56,000
HQ
Portage, MI, United States
Data: Yahoo Finance (yfinance)|Updated: Nov 20, 2026 06:18

Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.

Legal Disclaimer

This website is not a financial advisor, investment advisor, or financial services provider. We do not offer, recommend, or imply any investment advice of any kind. We do not receive compensation, commissions, or any other benefit from any company, fund, financial product, or third party featured on this site. No content on this website constitutes a recommendation or solicitation to buy, sell, or hold any security or financial instrument.

All financial analysis, ratios, and written commentary are provided for educational and informational purposes only. The Financial Analysis and Financial Investigation sections reflect automated computations applied to publicly available financial data — they do not represent the opinion of a licensed financial professional. Always conduct your own independent research and consult a qualified, regulated financial adviser before making any investment decision. Past performance of dividends, prices, or earnings is not a guarantee of future results.

Data Sources: Yahoo Finance via yfinance (real-time prices, dividend history, financial statements, analyst ratings and price targets) · S&P 500 Dividend Aristocrats Index (official constituent list) · Dividend Kings public records (companies with 50+ years of consecutive dividend increases) · SEC EDGAR company filings (10-K annual reports — primary source for all financial statement data). Data is fetched automatically each day and may be delayed up to 24 hours. All figures are in USD unless otherwise stated.